公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2017 | Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC | Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG ; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M. | Lung Cancer | 48 | 38 |